Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
European Journal of Neurology2020Vol. 27(11), pp. 2378–2380
Citations Over TimeTop 10% of 2020 papers
Makbule Şenel, Samir Abu‐Rumeileh, Detlef Michel, Tamara Garibashvili, Katharina Althaus, Jan Kassubek, Markus Otto
Abstract
Miller-Fisher syndrome (MFS) is classified as a variant of Guillain-Barré syndrome (GBS), accounting for 5%-25% of all GBS cases. Since the coronavirus disease-2019 (COVID-19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS-CoV-2 infection test.
Related Papers
- → Abnormalities of cerebrospinal fluid amino acids in patients with the Guillain-Barre syndrome.(1981)15 cited
- → Bickerstaff 's encephalitis, Guillain-Barré syndrome and idiopathic intracranial hypertension: are they related conditions?(2008)9 cited
- → Neurochemical analysis of cerebrospinal fluid(1980)102 cited
- → Guillain–Barre/Miller–Fisher overlap syndrome or acute, motor and sensory, axonal neuropathy with cranial nerve involvement?(2022)1 cited